The all-or-nothing strategy has landed the ‘pride of the pharmaceutical industry' in a situation that deteriorated rapidly.
A recent modification to the contract would have allowed Vaxart to invoice BARDA for the remaining $230 million or so for ...
Tixagevimab-cilgavimab reduced risk for severe COVID-19 progression in patients with hematologic malignancies on anti-CD20 therapy during the early Omicron era.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback